Laurus Labs share price (NSE: LAURUSLABS ) delivered an impressive performance in the first quarter of FY27, rising 53% between April and June 2026. This marks the company's strongest quarterly gain in the past 5 years, driven by robust growth in its Contract Development and Manufacturing Organisation (CDMO) business.
The stock also touched a record high of ₹1,530.30 during trading on 29 June 2026.
Over the past 5 trading days, the stock has gained 2.29%, adding ₹34.00. In the past 1 month, it has risen 9.33% or ₹129.60. The stock has surged 37.00% over the last 6 months, gaining ₹410.00, while it has advanced 109.42% or ₹793.15 over the past year. Looking at its long-term performance, Laurus Labs has generated an impressive 124.01% return over the past 5 years, with the share price increasing by ₹840.35.
The company's strong performance has been supported by continued growth in its CDMO business, particularly through commercial-stage contracts and late-stage development projects.
Laurus Labs said it continues to receive healthy clinical and commercial orders across different technologies and manufacturing sites, providing good visibility for future growth.
The company is also benefiting from the increasing commercialisation of newer projects.
Laurus Labs reported a solid financial performance during FY26.
| Financial Metric | FY26 |
| Revenue | ₹6,813 crore |
| Revenue Growth | 23% YoY |
| Gross Margin | Around 60% |
| EBITDA Margin | 26.8% |
| EBITDA Margin Expansion | 6.7 percentage points |
Revenue growth was mainly driven by the strong performance of the CDMO segment, supported by the company's affordable medicines and generics business.
Laurus Labs has steadily transformed its business model over the past several years.
The contribution from its CDMO business has increased from 13% six years ago to more than 30% in FY26. At the same time, dependence on its antiretroviral (ARV) business has reduced, with ARV revenue contribution falling from 67% to 41%.
The company's small molecule CDMO business generated ₹1,896 crore in revenue during FY26, representing a 38% increase over the previous year.
Growth was driven by:
According to its FY26 annual report, Laurus Labs is investing in several capital expenditure projects across high-growth business areas.
These investments include expanding manufacturing capacity and strengthening infrastructure across multiple technologies. The projects are expected to be completed over the next 2 years and are likely to enhance the company's global manufacturing capabilities.
Management also plans to:
Laurus Labs has delivered its strongest quarterly rally in 5 years as investors responded positively to the company's growing CDMO business, improving profitability and long-term expansion strategy.
For daily market updates and regular stock market news in Hindi, stay tuned to Angel One's share market news in Hindi.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks. Read all related documents carefully before investing.
Published on: Jun 30, 2026, 4:58 PM IST
Kusum Kumari
Kusum Kumari is a Content Writer with 4 years of experience in simplifying financial market concepts. Currently crafting insightful content at Angel One, She specialise in breaking down complex topics into easy-to-understand pieces, blending expertise in market fundamentals and technical analysis.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
